Food allergy, dermatologic diseases, and anaphylaxisPatient perspectives on the management of atopic dermatitis
Section snippets
Methods
The study was conducted in 8 countries between July and September 2004 (see Table E1 in the Online Repository at www.jacionline.org). Patients (>13 years) and caregivers (of children 2-13 years old) with moderate to severe AD as defined by their treating physician underwent in-depth telephone interviews apart from those in the United States and the United Kingdom, where interviews were conducted face to face to enable the EQ-5D15 questionnaire to be administered. The results of the EQ-5D will
Patient characteristics
A total of 2002 patients and caregivers from 8 countries took part in ISOLATE (see Table E1 in the Online Repository at www.jacionline.org). Sixty percent of the respondents were patients (>13 years), and 40% were caregivers looking after children (2-13 years). Table II shows that the distribution of patients by age, sex, and disease characteristics is similar to that of other published AD surveys.21 The proportion of patients with moderate-to-severe AD is also in line with the caseload of the
Discussion
The results of ISOLATE highlight AD as a condition that still has a significant physical and emotional effect on patients and caregivers despite the availability of effective treatment strategies and sources of patient support. Less than optimal disease control results in patients experiencing sleep deprivation, lack of concentration, and impaired school-work productivity. The resulting stigma of AD can also affect the patient's self-esteem, mood, self-confidence, and ability to establish and
References (21)
- et al.
Validation of the dermatology life quality index and the work productivity and activity impairment—chronic hand dermatitis questionnaire in chronic hand dermatitis
Am Acad Dermatol
(2003) Atopic dermatitis: immunology and treatment with immune modulators
Clin Exp Immunol
(1997)- et al.
Prevalence of atopic eczema in the community: the Lothian Atopic Dermatitis study
Br J Dermatol
(1996) - et al.
International consensus conference in atopic dermatitis II (ICCAD II): clinical update and current treatment strategies
Br J Dermatol
(2003) - et al.
Increase of asthma, allergic rhinitis and eczema in Swedish schoolchildren between 1979 and 1991
Clin Exp Allergy
(1995) - et al.
Changing prevalence of asthma in Australian children
BMJ
(1994) - et al.
Social impact of atopic dermatitis
Med Health R I
(2001) - et al.
Dermatology Life Quality Index (DLQI)—a simple practical measure for routine clinical use
Clin Exp Dermatol
(1994) - et al.
Atopic dermatitis is associated with a decrement in health-related quality of life
Int J Dermatol
(2002) Quality of life assessments in dermatology
Semin Cutan Med Surg
(1998)
Cited by (267)
A quantitative systems pharmacology workflow toward optimal design and biomarker stratification of atopic dermatitis clinical trials
2024, Journal of Allergy and Clinical ImmunologyBaricitinib treatment rapidly improves the four signs of atopic dermatitis assessed by Eczema Area and Severity Index (EASI) clinical subscores
2024, Journal of the European Academy of Dermatology and VenereologyThe Patient-Oriented Scoring of Atopic Dermatitis and SCORAD in young children: New data on interpretability and clinical usefulness
2024, Journal of the European Academy of Dermatology and VenereologyPatient education in atopic dermatitis: a scoping review
2023, Allergy, Asthma and Clinical Immunology
This study was supported by an unrestricted educational grant from Novartis Pharma AG.
Disclosure of potential conflict of interest: T. Zuberbier has consultant arrangements with and is on the speakers' bureau for Novartis. S. Orlow has consultant arrangements with and is on the speakers' bureau for Novartis and Astellas. A. Paller has speaker and consultant arrangements with Novartis. A. Taïeb has consultant arrangements with and has received a travel grant from Novartis. R. Allen is on the speakers' bureau for Novartis. J. Ocampo-Candiani has received a travel grant from Novartis. M. Cox works for the National Eczema Society, which works closely with the pharmaceutical industry. J. Langeraar works for the Nation Eczema Association for Science and Education, which has received financial support from Astellas and Novartis. J. Simon has consultant arrangements with and is on the speakers' bureau for Novartis.